铽-161 [161Tb]Tb-DOTATATE在复发性副神经节瘤中的应用。

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2025-11-01 Epub Date: 2025-05-16 DOI:10.1097/RLU.0000000000005897

Nihaad Jacobs, Tariq Solomon, Olumayowa Kolade, Khanyisile Hlongwa, Stuart More

{"title":"铽-161 [161Tb]Tb-DOTATATE在复发性副神经节瘤中的应用。","authors":"Nihaad Jacobs, Tariq Solomon, Olumayowa Kolade, Khanyisile Hlongwa, Stuart More","doi":"10.1097/RLU.0000000000005897","DOIUrl":null,"url":null,"abstract":"This report explores the application of terbium-161 [( 161 Tb)Tb] DOTATATE in the case of a 31-year-old man with recurrent paraganglioma. Due to liver metastases and inoperable nodal disease, he was treated with lutetium-177 [( 177 Lu)Lu] DOTATATE, resulting in decreased chromogranin A levels and stable disease. Logistical challenges with lutetium-177 acquisition resulted in treatment with [ 161 Tb]Tb-DOTATATE, demonstrating prominent lesion uptake, further reduction in chromogranin A levels, and no adverse effects. He maintains an excellent functional status and 19 months of progression-free survival after 3 total cycles of [ 177 Lu]Lu and [ 161 Tb]Tb-DOTATATE, suggesting [ 161 Tb]Tb-DOTATATE as a promising alternative radionuclide therapy for advanced neuroendocrine tumors.","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"1076-1077"},"PeriodicalIF":9.6000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of Terbium-161 [ 161 Tb]Tb-DOTATATE in Recurrent Paraganglioma.\",\"authors\":\"Nihaad Jacobs, Tariq Solomon, Olumayowa Kolade, Khanyisile Hlongwa, Stuart More\",\"doi\":\"10.1097/RLU.0000000000005897\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This report explores the application of terbium-161 [( 161 Tb)Tb] DOTATATE in the case of a 31-year-old man with recurrent paraganglioma. Due to liver metastases and inoperable nodal disease, he was treated with lutetium-177 [( 177 Lu)Lu] DOTATATE, resulting in decreased chromogranin A levels and stable disease. Logistical challenges with lutetium-177 acquisition resulted in treatment with [ 161 Tb]Tb-DOTATATE, demonstrating prominent lesion uptake, further reduction in chromogranin A levels, and no adverse effects. He maintains an excellent functional status and 19 months of progression-free survival after 3 total cycles of [ 177 Lu]Lu and [ 161 Tb]Tb-DOTATATE, suggesting [ 161 Tb]Tb-DOTATATE as a promising alternative radionuclide therapy for advanced neuroendocrine tumors.\",\"PeriodicalId\":10692,\"journal\":{\"name\":\"Clinical Nuclear Medicine\",\"volume\":\" \",\"pages\":\"1076-1077\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/RLU.0000000000005897\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005897","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

本报告探讨了terbium-161 [(161Tb)Tb] DOTATATE在31岁男性复发副神经节瘤病例中的应用。由于肝转移和无法手术的淋巴结病，他接受了镥-177 [(177Lu)Lu] DOTATATE治疗，导致嗜铬粒蛋白A水平下降，病情稳定。在使用[161Tb]Tb-DOTATATE治疗时，由于对镥-177的获取存在后勤上的困难，结果显示病变吸收明显，嗜铬粒蛋白A水平进一步降低，且无不良反应。在接受[177Lu]Lu和[161Tb]Tb-DOTATATE治疗3个周期后，患者保持了良好的功能状态和19个月的无进展生存期，提示[161Tb]Tb-DOTATATE是晚期神经内分泌肿瘤的一种有前景的替代放射性核素治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Use of Terbium-161 [ 161 Tb]Tb-DOTATATE in Recurrent Paraganglioma.

This report explores the application of terbium-161 [( 161 Tb)Tb] DOTATATE in the case of a 31-year-old man with recurrent paraganglioma. Due to liver metastases and inoperable nodal disease, he was treated with lutetium-177 [( 177 Lu)Lu] DOTATATE, resulting in decreased chromogranin A levels and stable disease. Logistical challenges with lutetium-177 acquisition resulted in treatment with [ 161 Tb]Tb-DOTATATE, demonstrating prominent lesion uptake, further reduction in chromogranin A levels, and no adverse effects. He maintains an excellent functional status and 19 months of progression-free survival after 3 total cycles of [ 177 Lu]Lu and [ 161 Tb]Tb-DOTATATE, suggesting [ 161 Tb]Tb-DOTATATE as a promising alternative radionuclide therapy for advanced neuroendocrine tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.